Puretech Health Plc Stock Analysis
| PTCHF Stock | USD 1.70 0.15 8.11% |
PureTech Health plc holds a debt-to-equity ratio of 0.083. PureTech Health's financial risk is the risk to PureTech Health stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
PureTech Health's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. PureTech Health's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps PureTech Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect PureTech Health's stakeholders.
For many companies, including PureTech Health, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for PureTech Health plc, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, PureTech Health's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that PureTech Health's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which PureTech Health is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of PureTech Health to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, PureTech Health is said to be less leveraged. If creditors hold a majority of PureTech Health's assets, the Company is said to be highly leveraged.
PureTech Health plc is fairly valued with Real Value of 1.7 and Hype Value of 1.7. The main objective of PureTech Health pink sheet analysis is to determine its intrinsic value, which is an estimate of what PureTech Health plc is worth, separate from its market price. There are two main types of PureTech Health's stock analysis: fundamental analysis and technical analysis.
The PureTech Health pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and PureTech Health's ongoing operational relationships across important fundamental and technical indicators.
PureTech |
PureTech Pink Sheet Analysis Notes
About 15.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.61. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. PureTech Health plc has Price/Earnings (P/E) ratio of 158.0. The entity recorded a loss per share of 0.21. The firm had not issued any dividends in recent years. PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. PURETECH HEALTH operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 95 people.The quote for PureTech Health plc is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about PureTech Health plc contact Daphne Zohar at 617 482 2333 or learn more at https://www.puretechhealth.com.PureTech Health plc Investment Alerts
| PureTech Health plc may become a speculative penny stock | |
| The company reported the revenue of 9.98 M. Net Loss for the year was (60.56 M) with profit before overhead, payroll, taxes, and interest of 17.39 M. | |
| PureTech Health plc has accumulated about 368.03 M in cash with (158.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28. | |
| Roughly 72.0% of the company shares are owned by institutional investors |
PureTech Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 901.7 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate PureTech Health's market, we take the total number of its shares issued and multiply it by PureTech Health's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.PureTech Profitablity
The company has Profit Margin (PM) of (0.73) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (9.87) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $9.87.Technical Drivers
As of the 19th of February, PureTech Health holds the Variance of 3.61, coefficient of variation of 5283.04, and Risk Adjusted Performance of 0.0208. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of PureTech Health, as well as the relationship between them. Please check PureTech Health plc information ratio, and the relationship between the coefficient of variation and value at risk to decide if PureTech Health plc is priced some-what accurately, providing market reflects its current price of 1.7 per share. Please also confirm PureTech Health plc jensen alpha, which is currently at 0.0238 to check out the company can sustain itself at a future point.PureTech Health plc Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.
PureTech Health Outstanding Bonds
PureTech Health issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. PureTech Health plc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most PureTech bonds can be classified according to their maturity, which is the date when PureTech Health plc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
PureTech Health Predictive Daily Indicators
PureTech Health intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of PureTech Health pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Rate Of Daily Change | 0.92 | |||
| Day Median Price | 1.7 | |||
| Day Typical Price | 1.7 | |||
| Price Action Indicator | (0.07) | |||
| Period Momentum Indicator | (0.15) | |||
| Relative Strength Index | 82.92 |
PureTech Health Forecast Models
PureTech Health's time-series forecasting models are one of many PureTech Health's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary PureTech Health's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.PureTech Health plc Debt to Cash Allocation
Many companies such as PureTech Health, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
PureTech Health plc has accumulated 14.26 M in total debt with debt to equity ratio (D/E) of 0.08, which may suggest the company is not taking enough advantage from borrowing. PureTech Health plc has a current ratio of 2.49, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist PureTech Health until it has trouble settling it off, either with new capital or with free cash flow. So, PureTech Health's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PureTech Health plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PureTech to invest in growth at high rates of return. When we think about PureTech Health's use of debt, we should always consider it together with cash and equity.PureTech Health Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the PureTech Health's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of PureTech Health, which in turn will lower the firm's financial flexibility.PureTech Health Corporate Bonds Issued
Most PureTech bonds can be classified according to their maturity, which is the date when PureTech Health plc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About PureTech Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how PureTech Health prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling PureTech shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as PureTech Health. By using and applying PureTech Pink Sheet analysis, traders can create a robust methodology for identifying PureTech entry and exit points for their positions.
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. PURETECH HEALTH operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 95 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding PureTech Health to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Global Markets Map Now
Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
| All Next | Launch Module |
Complementary Tools for PureTech Pink Sheet analysis
When running PureTech Health's price analysis, check to measure PureTech Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PureTech Health is operating at the current time. Most of PureTech Health's value examination focuses on studying past and present price action to predict the probability of PureTech Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PureTech Health's price. Additionally, you may evaluate how the addition of PureTech Health to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |